Skip to main content

Press Releases

Date Title
Toggle Summary Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
WESTLAKE VILLAGE, Calif. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to
Toggle Summary Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019
-- 27% of subjects achieved 75% reduction in PASI score (PASI 75) vs 13% with vehicle; 29% of subjects achieved two-grade improvement on IGA and ‘clear’ or ‘almost clear’ skin vs 13% with vehicle (statistically significant) -- Subjects achieved 58% improvement in itch from baseline on the I-NRS vs
Toggle Summary Sienna Biopharmaceuticals® Reports Third Quarter 2018 Financial Results
WESTLAKE VILLAGE, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today reported the Company’s financial results for the third quarter of 2018. “We are pleased to report the results of our third

SEC Filings

Events

Date Title
Summary Toggle Dec 3, 2018 at 8:15 AM EST
Summary Toggle Dec 12, 2018 at 10:20 AM EST
Prescriptions for Success Healthcare Conference

Webcast events that have already occurred are presented for historical purposes only and speak only as of the date thereof.

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Refresh quote

Analyst Coverage

Firm Analyst
J.P. Morgan
Chris Schott
Cowen
Ken Cacciatore
BMO Capital Markets
Gary Nachman

The analysts above have initiated and are maintaining formal research coverage of Sienna. Please note that any opinions, estimates or forecasts regarding Sienna’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sienna or Sienna’s management. Sienna does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Sienna does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

Transfer Agent

EQ Shareowner Services
www.shareowneronline.com

IR Contact

IR@SiennaBio.com

Media Contact

media@SiennaBio.com